Frontera Therapeutics A Global Clinical-Stage Biotechnology Company That Seeks To Develop Novel And Best-In-Class Gene Therapy Medicines To Improve The Lives Of Patients Across Multiple Disease Areas, Announced That It Has Dosed The First Patient In A Clinical Trial Of Its Innovative Gene Therapy Product, Ft-003, At The Ophthalmology Hospital Of Tianjin Medical University In Tianjin, China. Ft-003 Is Being Studied For The Treatment Of Neovascular Or Wet Age-Related Macular Degeneration (Wamd) And Is Frontera
